Abstract
Cancer therapy is facing the big challenge of destroying selectively tumour cells without harming the normal tissues. Chemotherapy was trying from the beginning to kill malignant cells because of their proliferative activity since normal cells are in general quiescent. Meanwhile side effects were produced due to the destruction of some normal cells that need regular proliferation. The discovery of biomarkers led to the identification of molecular targets within tumour cells in order to kill them selectively. Chemistry followed the progress of biomarkers biotechnology by the production of target specific antagonists which were the subject of many patents. Meanwhile novel problems of tumour resistance appeared and made the battle against cancer a non stop development of new strategies and new weapons. As a consequence, paralleled activities of patenting biomarkers and chemical antagonists are continuously generated. The offer of chemistry does not actually limit the efficiency of Targeted therapy but the identification of biomarkers is still missing the exclusive specificity to tumour cells.
Keywords: Drug approval, neoplasms, cells, drug therapy, combination, drug targeting, efficiency, antagonists and inhibitors, mutation, patients, cell proliferation, proto-oncogene, drug resistance, molecular targeted therapy, united states food and drug administration, screening, target, anti-angiogenic agents
Recent Patents on Biotechnology
Title: The Offer of Chemistry to Targeted Therapy in Cancer
Volume: 5 Issue: 3
Author(s): Ikram Jemel, Karim Jellali, Jihene Elloumi and Sami Aifa
Affiliation:
Keywords: Drug approval, neoplasms, cells, drug therapy, combination, drug targeting, efficiency, antagonists and inhibitors, mutation, patients, cell proliferation, proto-oncogene, drug resistance, molecular targeted therapy, united states food and drug administration, screening, target, anti-angiogenic agents
Abstract: Cancer therapy is facing the big challenge of destroying selectively tumour cells without harming the normal tissues. Chemotherapy was trying from the beginning to kill malignant cells because of their proliferative activity since normal cells are in general quiescent. Meanwhile side effects were produced due to the destruction of some normal cells that need regular proliferation. The discovery of biomarkers led to the identification of molecular targets within tumour cells in order to kill them selectively. Chemistry followed the progress of biomarkers biotechnology by the production of target specific antagonists which were the subject of many patents. Meanwhile novel problems of tumour resistance appeared and made the battle against cancer a non stop development of new strategies and new weapons. As a consequence, paralleled activities of patenting biomarkers and chemical antagonists are continuously generated. The offer of chemistry does not actually limit the efficiency of Targeted therapy but the identification of biomarkers is still missing the exclusive specificity to tumour cells.
Export Options
About this article
Cite this article as:
Jemel Ikram, Jellali Karim, Elloumi Jihene and Aifa Sami, The Offer of Chemistry to Targeted Therapy in Cancer, Recent Patents on Biotechnology 2011; 5 (3) . https://dx.doi.org/10.2174/187220811797579079
DOI https://dx.doi.org/10.2174/187220811797579079 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
Call for Papers in Thematic Issues
Advancements in Plant Genetics and Genomics
This thematic issue will highlight cutting-edge innovations and recent patents across the breadth of plant genetics and genomics. Key topics will include advanced breeding techniques, omics-based approaches, gene editing, trait discovery, and translational applications for crop improvement. Renowned researchers from leading institutions worldwide will provide state-of-the-art insights and future perspectives ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Signal Transducer and Activator of Transcription 5 (STAT5), a Crucial Regulator of Immune and Cancer Cells
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway
Current Pharmaceutical Design Angiogenesis Inhibitors and Radiation in Multimodality Cancer Therapy: Preclinical and Clinical Studies
Current Angiogenesis (Discontinued) Recent Advances in Oral Pulsatile Drug Delivery
Recent Patents on Drug Delivery & Formulation Impact of Metformin on Male Reproduction
Current Pharmaceutical Design Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Synthesis, Characterization, and Biological Evaluation of Novel Naringenin Derivatives as Anticancer Agents
Current Bioactive Compounds Role of Carboplatin in the Treatment of Triple Negative Early- Stage Breast Cancer
Reviews on Recent Clinical Trials Transient Receptor Potential Vanilloid 1 Channel Modulation: A Novel Approach to Pain Therapy
Current Bioactive Compounds Berberine Exerts Anti-cancer Activity by Modulating Adenosine Monophosphate- Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/ Protein Kinase B (PI3K/AKT) Signaling Pathways
Current Pharmaceutical Design Mitochondria and Familial Predisposition to Breast Cancer
Current Genomics AMPK: Therapeutic Target for Diabetes and Cancer Prevention
Current Pharmaceutical Design Mucosal Healing in Ulcerative Colitis: Where do we Stand?
Current Drug Targets Phytochemicals in Anticancer Drug Development
Anti-Cancer Agents in Medicinal Chemistry Anticancer Activity of an Oplopanax elatus Stem Extract and Biologically Active Isolated Compounds
Current Pharmaceutical Biotechnology They Must Hold Tight: Junction Proteins, Microbiota And Immunity In Intestinal Mucosa
Current Protein & Peptide Science Central Nervous System Involvement in Pediatric Rheumatic Diseases: Current Concepts in Treatment
Current Pharmaceutical Design Treatments for Iron Deficiency (ID): Prospective Organic Iron Fortification
Current Pharmaceutical Design Synthesis, in vitro Antiproliferative and Antiinflammatory Activities, and Kinase Inhibitory effects of New 1,3,4-triarylpyrazole Derivatives
Anti-Cancer Agents in Medicinal Chemistry The Biphasic Expression Pattern of miR-200a and E-cadherin in Epithelial Ovarian Cancer and its Correlation with Clinicopathological Features
Current Pharmaceutical Design